Eli Lilly
Pays vs peer median
×1.09
+9% premium
Sample
26
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.16 | 20 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.22 | 7 |
| phase 3 | ×1.01 | 5 |
| phase 2 | ×1.07 | 4 |
| discovery | ×0.70 | 4 |
| preclinical | ×1.50 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Five-program multi-asset partnership | Haisco | metabolic and other indications | unknown | — | $3.0B |
| 2026 | RNA exon editing platform | Ascidian | genetically driven kidney diseases | discovery | — | $1.9B |
| 2026 | 5-program collaboration (undisclosed programs) | Haisco | — | unknown | — | $3.0B |
| 2026 | sonefpeglutide | Hanmi Pharm | short bowel syndrome | phase_2 | $75M | $1.2B |
| 2026 | GLP-2 drug | Hanmi | — | unknown | — | $1.2B |
| 2026 | DNA delivery platform | Engage Bio | — | unknown | — | $202M |
| 2026 | Next-generation shingles (herpes zoster) vaccine | Curevo Vaccine | herpes zoster (shingles) | phase_3 | — | $1.5B |
| 2026 | LTB-SA7 and bacterial vaccine platform | LimmaTech Biologics | bacterial infections including gonorrhea | phase_1 | — | $780M |
| 2026 | Undisclosed EBV vaccine program | Vaccine Company (undisclosed third vaccine developer) | Epstein-Barr virus (EBV) | preclinical | — | $1.6B |
| 2026 | Verve gene-editing cardiovascular programs | Verve Therapeutics | cardiovascular disease | unknown | $1.0B | $2.3B |
| 2026 | JAK inhibitor (lead small molecule) | Ajax Therapeutics | myelofibrosis | preclinical | — | $2.3B |
| 2026 | dual-payload ADC platform | Unnamed ADC company | oncology | discovery | — | $300M |
| 2026 | DNA delivery platform (non-viral genetic medicines) | Engage Bio | genetic diseases | preclinical | — | $200M |
| 2026 | in vivo cell therapy candidate | Kelonia Therapeutics | multiple myeloma | preclinical | — | $7.0B |
| 2026 | non-viral genetic medicines platform | unnamed DNA delivery biotech | — | preclinical | — | $300M |
How this is computed
For each Eli Lilly deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 26 disclosed deal premiums vs. peer medians. Raw premium 1.090, clamped to [0.7, 1.5].